Andrew Norwich is a corporate partner in the New York office of Kirkland & Ellis LLP. His practice primarily focuses on public and private company merger and acquisition transactions and activist defense. Andrew also advises corporations and their directors on general corporate and governance matters.
Experience
Representative Matters
Prior to and since joining Kirkland, Andrew’s representative matters include:
Walgreens Boots Alliance in its pending $23.7 billion sale to Sycamore Partners
Amcor in its pending $37 billion merger with Berry Global
PowerSchool in its $5.6 billion sale to Bain Capital
Vista Equity Partners in its $8.4 billion acquisition of Smartsheet
Crown Laboratories, a portfolio company of Hildred Capital Management:
in its pending $924 million agreement to acquire Revance Therapeutics
in its amended $325 million agreement to acquire Revance Therapeutics
Perella Weinberg Partners as financial advisor to Shockwave Medical in its $13.1 billion sale to Johnson & Johnson
Evolution on its acquisition of Galaxy Gaming
Alight Solutions in its $1.2 billion sale of its Payroll and Professional Services business to H.I.G. Capital*
Sixth Street in the Sixth Street-led consortium acquisition of GreenSky from Goldman Sachs*
IBM in its $222 million acquisition of Randori*
Novartis in its $2.1 billion acquisition of Endocyte*
Ole Smoky Distillery, a portfolio company of Apax Partners, in connection with its acquisition of Tanteo Spirits*
LexisNexis Legal & Professional, part of RELX Group, in its joint venture with Knowable*
Knorr-Bremse in its $150 million acquisition of R.H. Sheppard*
Peter J. Solomon in connection with a share reclassification agreement with Monro, Inc.*
